Despite molecular and clinical heterogeneity, small cell lung cancer (SCLC) is treated as a
single entity with predictably poor results. Using tumor expression data and non-negative …

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …

Small cell lung cancer (SCLC) is an extremely aggressive neuroendocrine tumor,
accounting for approximated 13% of all lung cancer cases. SCLC is characterized by rapid …

Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid growth,
early metastasis, and acquired therapeutic resistance. A majority of patients with SCLC have …

Small cell lung cancer (SCLC) is a particular subtype of lung cancer with high mortality.
Recent advances in understanding SCLC genomics and breakthroughs of immunotherapy …

Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Summary Atezolizumab (anti-PD-L1), combined with carboplatin and etoposide (CE), is now
a standard of care for extensive-stage small-cell lung cancer (ES-SCLC). A clearer …

Small cell lung cancer (SCLC; accounting for approximately 13%–15% of all lung cancers)
is an exceptionally lethal malignancy characterized by rapid doubling time and high …

Simple Summary Small cell lung cancer (SCLC) is an aggressive cancer representing 15%
of all lung cancers. Unlike other types of lung cancer, treatments for SCLC have changed …

The tissue distribution and prognostic relevance of subtype‐specific proteins (ASCL1,
NEUROD1, POU2F3, YAP1) present an evolving area of research in small‐cell lung cancer …